Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Pain and Headache Reports
Erschienen in: Current Pain and Headache Reports 10/2023

05.08.2023 | Hot Topics in Pain and Headache (N Rosen, Section Editor)

The Role of Step Therapy in the Treatment of Migraine

verfasst von: Leon S. Moskatel, Niushen Zhang

Erschienen in: Current Pain and Headache Reports | Ausgabe 10/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review examines recent evidence and applies bioethical principles to evaluate the benefits and risks of using step therapy in the treatment of migraine.

Recent Findings

With the CGRP mAbs, gepants, and lasmiditan now on the market for up to 5 years, new research, including network meta-analyses and long-term use studies, can evaluate the comparative efficacy, tolerability, and adherence of these medications relative to older acute and preventive medications for the treatment of migraine.

Summary

Deciding how medications are chosen for patients requires accounting for many factors including sustainability, efficacy, tolerability, and preference. Newer research can help give clarity on the appropriateness of gating certain treatment options behind others.
Literatur
1.
Vos T, Barber RM, Bell B, Bertozzi-Villa A, Biryukov S, Bolliger I, Charlson F, Davis A, Degenhardt L, Dicker D, Duan L. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(9995):743–800.CrossRef
2.
Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: updated age, sex, and socioeconomic‐specific estimates from government health surveys. Headache: J Head Face Pain. 2021;61(1):60–8.
3.
Raval AD, Shah A. National trends in direct health care expenditures among US adults with migraine: 2004 to 2013. J Pain. 2017;18(1):96–107.CrossRefPubMed
4.
• Gilligan AM, Foster SA, Sainski-Nguyen A, Sedgley R, Smith D, Morrow P. Direct and indirect costs among United States commercially insured employees with migraine. J Occup Environ Med. 2018;60(12):1120–7. Assessment of healthcare costs of patients with migraine.
5.
Devine J, Hadsall R, Cline R, Schommer J, Virnig B. Effect of daily migraine prevention on health care utilisation in an insured patient population. J Headache Pain. 2007;8:105–13.CrossRefPubMedPubMedCentral
6.
Lainez MJ. The effect of migraine prophylaxis on migraine-related resource use and productivity. CNS Drugs. 2009;23:727–38.CrossRefPubMed
7.
Wertz DA, Quimbo RM, Yaldo AZ, Rupnow MF. Resource utilization impact of topiramate for migraine prevention in the managed-care setting. Curr Med Res Opin. 2009;25(2):499–503.CrossRefPubMed
8.
Borges dos Santos MA, dos Santos Dias LL, Santos Pinto CD, da Silva RM, Osorio-de-Castro CG. Factors influencing pharmaceutical pricing-a scoping review of academic literature in health science. J Pharm Policy Pract. 2019;12:1–2.
9.
10.
11.
12.
13.
Hoffman S. Step therapy. Food Drug Law J. 2018;73(1):38–65.
14.
Sedghi T, Gronbeck C, Aiudi DA, Grant-Kels JM. Assessing the ethics of prior authorization denials and step therapy policies in dermatology. J Am Acad Dermatol. 2023.
15.
Silberstein SD, Winner PK, Chmiel JJ. Migraine preventive medication reduces resource utilization. Headache: J Head Face Pain. 2003;43(3):171–8.
16.
Etemad LR, Yang W, Globe D, Barlev A, Johnson KA. Costs and utilization of triptan users who receive drug prophylaxis for migraine versus triptan users who do not receive drug prophylaxis. J Manag Care Pharm. 2005;11(2):137–44.PubMed
17.
Feliu AL, Rupnow MF, Blount A, Boccuzzi SJ, Vermilyea J. Resource use associated with topiramate in migraine prophylaxis. Am J Health-Syst pharm. 2007;64(14):1483–91.CrossRefPubMed
18.
Silberstein SD, Feliu AL, Rupnow MF, Blount AC, Boccuzzi SJ. Topiramate in migraine prophylaxis: long‐term impact on resource utilization and cost. Headache: J Head Face Pain. 2007;47(4):500–10.
19.
• Foster SA, Hoyt M, Ye W, Mason O, Ford JH. Direct cost and healthcare resource utilization of patients with migraine before treatment initiation with calcitonin gene-related peptide monoclonal antibodies by the number of prior preventive migraine medication classes. Curr Med Res Opin. 2022;38(5):653–60. Examines underexplored topic of economic effect of medication non-responders.
20.
Khanal S, Underwood M, Naghdi S, Brown A, Duncan C, Matharu M, Mistry H. A systematic review of economic evaluations of pharmacological treatments for adults with chronic migraine. J Headache Pain. 2022;23(1):122.CrossRefPubMedPubMedCentral
21.
Rothrock JF, Bloudek LM, Houle TT, Andress‐Rothrock D, Varon SF. Real‐world economic impact of onabotulinumtoxin A in patients with chronic migraine. Headache: J Head Face Pain. 2014;54(10):1565–73.
22.
Messali A, Owens G, Bloudek L, Kori S, Cole A, Chia J. Health care resource utilization following initiation of a triptan: a retrospective claims analysis. J Manag Care Pharm. 2014;20(4):368–75.
23.
Marcus SC, Shewale AR, Silberstein SD, Lipton RB, Young WB, Viswanathan HN, Doshi JA. Comparison of healthcare resource utilization and costs among patients with migraine with potentially adequate and insufficient triptan response. Cephalalgia. 2020;40(7):639–49.CrossRefPubMedPubMedCentral
24.
25.
Wilper A, Woolhandler S, Himmelstein D, Nardin R. Impact of insurance status on migraine care in the United States: a population-based study. Neurology. 2010;74(15):1178–83.CrossRefPubMed
26.
Minen MT, Lindberg K, Langford A, Loder E. Variation in prescription drug coverage for triptans: analysis of insurance formularies. Headache: J Head Face Pain. 2017;57(8):1243–51.
27.
Wang V, Bieser S, Lowe A, Li M, Yuan H. CGRP antagonist (gepant) vs triptan use profiles in individuals with migraine: a multicenter electronic medical record analysis of patient characteristics and emergency department services utilization (P6–12.010).
28.
• Jackson JL, Cogbill E, Santana-Davila R, Eldredge C, Collier W, Gradall A, Sehgal N, Kuester J. A comparative effectiveness meta-analysis of drugs for the prophylaxis of migraine headache. PloSOne. 2015;10(7):e0130733. Older but thorough examination of comparative efficacy of preventive medication.
29.
• Ehrlich M, Hentschke C, Sieder C, Maier-Peuschel M, Reuter U. Erenumab versus topiramate: post hoc efficacy analysis from the HER-MES study. J Headache Pain. 2022;23(1):1–8. One of only studies comparing a CGRP mAb with an oral preventive.
30.
Overeem LH, Raffaelli B, Mecklenburg J, Kelderman T, Neeb L, Reuter U. Indirect comparison of topiramate and monoclonal antibodies against CGRP or its receptor for the prophylaxis of episodic migraine: a systematic review with meta-analysis. CNS Drugs. 2021;35:805–20.CrossRefPubMedPubMedCentral
31.
•• Frank F, Ulmer H, Sidoroff V, Broessner G. CGRP-antibodies, topiramate and botulinum toxin type A in episodic and chronic migraine: a systematic review and meta-analysis. Cephalalgia. 2021;41(11–12):1222–39. Comparison of CGRP mAbs, onabotA, and an oral preventive.
32.
Alpuente A, Gallardo VJ, Caronna E, Torres-Ferrús M, Pozo-Rosich P. Partial and nonresponders to onabotulinumtoxinA can benefit from anti-CGRP monoclonal antibodies preventive treatment: a real-world evidence study. Euro J Neurol. 2021;28(7):2378–82.CrossRef
33.
Goldstein J, Silberstein SD, Saper JR, Ryan Jr RE, Lipton RB. Acetaminophen, aspirin, and caffeine in combination versus ibuprofen for acute migraine: results from a multicenter, double‐blind, randomized, parallel‐group, single‐dose, placebo‐controlled study. Headache: J Head Face Pain. 2006;46(3):444–53.
34.
Jafari S, Khayyamfar F, Ansari I, Jafari R, Afshinmajd S. Comparison of ibuprofen and AAC (acetaminophen, aspirin, caffeine) for treating acute migraine episodes. J Basic Clin Pathophysiol. 2018;6(2):1–6.
35.
Misra UK, Kalita J, Yadav RK. Rizatriptan vs. ibuprofen in migraine: a randomised placebo-controlled trial. J Headache Pain. 2007;8:175–9.
36.
Pini LA, Guerzoni S, Cainazzo M, Ciccarese M, Prudenzano MP, Livrea P. Comparison of tolerability and efficacy of a combination of paracetamol+ caffeine and sumatriptan in the treatment of migraine attack: a randomized, double-blind, double-dummy, cross-over study. J Headache Pain. 2012;13:669–75.CrossRefPubMedPubMedCentral
37.
Goldstein J, Silberstein SD, Saper JR, Elkind AH, Smith TR, Gallagher RM, Battikha JP, Hoffman H, Baggish J. Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: results from the ASSET trial. Headache: J Head Face Pain. 2005;45(8):973–82.
38.
Lipton RB, Bigal ME, Goadsby PJ. Double-blind clinical trials of oral triptans vs other classes of acute migraine medication—a review. Cephalalgia. 2004;24(5):321–32.CrossRefPubMed
39.
Xu H, Han W, Wang J, Li M. Network meta-analysis of migraine disorder treatment by NSAIDs and triptans. J Headache Pain. 2016;17(1):1–8.CrossRef
40.
Hou M, Liu H, Li Y, Xu L, He Y, Lv Y, Zheng Q, Li L. Efficacy of triptans for the treatment of acute migraines: a quantitative comparison based on the dose-effect and time-course characteristics. Euro J Clin Pharmacol. 2019;75:1369–78.CrossRef
41.
•• Johnston K, Popoff E, Deighton A, Dabirvaziri P, Harris L, Thiry A, Croop R, Coric V, L’Italien G, Moren J. Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis. Expert Rev Pharmacoecon Outcomes Res. 2022;22(1):155–66. One of few studies looking at comparative efficacy and tolerability of the gepants and lasmiditan.
42.
•• Yang CP, Liang CS, Chang CM, Yang CC, Shih PH, Yau YC, Tang KT, Wang SJ. Comparison of new pharmacologic agents with triptans for treatment of migraine: a systematic review and meta-analysis. JAMA network open. 2021;4(10):e2128544-. Comparison of new and old acute treatments for migraine.
43.
Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015;35(6):478–88.CrossRefPubMed
44.
He A, Song D, Zhang L, Li C. Unveiling the relative efficacy, safety and tolerability of prophylactic medications for migraine: pairwise and network-meta analysis. J Headache Pain. 2017;18(1):1–7.CrossRef
45.
Vécsei L, Majláth Z, Szok D, Csáti A, Tajti J. Drug safety and tolerability in prophylactic migraine treatment. Expert Opin Drug Saf. 2015;14(5):667–81.CrossRefPubMed
46.
Kangasniemi P, Hedman C. Metoprolol and propranolol in the prophylactic treatment of classical and common migraine. A double-blind study Cephalalgia. 1984;4(2):91–6.PubMed
47.
Couch JR, Amitriptyline Versus Placebo Study Group. Amitriptyline in the prophylactic treatment of migraine and chronic daily headache. Headache: J Head Face Pain. 2011;51(1):33–51.
48.
Couch JR, Hassanein RS. Amitriptyline in migraine prophylaxis. Arch Neurol. 1979;36(11):695–9.CrossRefPubMed
49.
Ahmed F, Gaul C, García-Moncó JC, Sommer K, Martelletti P. An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study. J Headache Pain. 2019;20(1):1–4.CrossRef
50.
Guerzoni S, Pellesi L, Baraldi C, Cainazzo MM, Negro A, Martelletti P, Pini LA. Long-term treatment benefits and prolonged efficacy of onabotulinumtoxinA in patients affected by chronic migraine and medication overuse headache over 3 years of therapy. Front Neurol. 2017;8:586.CrossRefPubMedPubMedCentral
51.
Argyriou AA, Dermitzakis EV, Vlachos GS, Vikelis M. Long-term adherence, safety, and efficacy of repeated onabotulinumtoxinA over five years in chronic migraine prophylaxis. Acta Neurol Scand. 2022;145(6):676–83.CrossRefPubMed
52.
Yalinay Dikmen P, Kosak S, Ilgaz Aydinlar E, Sagduyu KA. A single-center retrospective study of onabotulinumtoxinA for treatment of 245 chronic migraine patients: survey results of a real-world experience. Acta Neurol Belg. 2018;118(3):475–84.CrossRefPubMed
53.
Vandervorst F, Van Deun L, Van Dycke A, Paemeleire K, Reuter U, Schoenen J, Versijpt J. CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs. J Headache Pain. 2021;22:1–1.CrossRef
54.
Krasenbaum LJ, Pedarla VL, Thompson SF, Tangirala K, Cohen JM, Driessen MT. A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United States. J Headache Pain. 2022;23(1):54.CrossRefPubMedPubMedCentral
55.
Pozo-Rosich P, Detke HC, Wang S, Doležil D, Li LQ, Aurora SK, Reuter U. Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study. Curr Med Res Opin. 2022;38(5):731–42.CrossRefPubMed
56.
Tinsley A, Rothrock JF. Safety and tolerability of preventive treatment options for chronic migraine. Expert Opin Drug Saf. 2021;20(12):1523–33.CrossRefPubMed
57.
Camporeale A, Kudrow D, Sides R, Wang S, Van Dycke A, Selzler KJ, Stauffer VL. A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine. BMC Neurol. 2018;18(1):1–2.CrossRef
58.
Lambru G, Hill B, Murphy M, Tylova I, Andreou AP. A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain. 2020;21:1.CrossRef
59.
Ornello R, Casalena A, Frattale I, Gabriele A, Affaitati G, Giamberardino MA, Assetta M, Maddestra M, Marzoli F, Viola S, Cerone D. Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain. 2020;21:1–1.CrossRef
60.
Saely S, Croteau D, Jawidzik L, Brinker A, Kortepeter C. Hypertension: a new safety risk for patients treated with erenumab. Headache: J Head Face Pain. 2021;61(1):202–8.
61.
Ashina M, Kudrow D, Reuter U, Dolezil D, Silberstein S, Tepper SJ, Xue F, Picard H, Zhang F, Wang A, Zhou Y. Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: a pooled analysis of four placebo-controlled trials with long-term extensions. Cephalalgia. 2019;39(14):1798–808.CrossRefPubMed
62.
•• Ashina M, Goadsby PJ, Reuter U, Silberstein S, Dodick DW, Xue F, Zhang F, Paiva da Silva Lima G, Cheng S, Mikol DD. Long‐term efficacy and safety of erenumab in migraine prevention: results from a 5‐year, open‐label treatment phase of a randomized clinical trial. European journal of neurology. 2021 May;28(5):1716–25. Longest study to date on efficacy and safety of a CGRP mAb.
63.
Thorlund K, Toor K, Wu P, Chan K, Druyts E, Ramos E, Bhambri R, Donnet A, Stark R, Goadsby PJ. Comparative tolerability of treatments for acute migraine: a network meta-analysis. Cephalalgia. 2017;37(10):965–78.CrossRefPubMed
64.
Lipton RB, Marcus SC, Shewale AR, Dodick DW, Viswanathan HN, Doshi JA. Acute treatment patterns in patients with migraine newly initiating a triptan. Cephalalgia. 2020;40(5):437–47.CrossRefPubMedPubMedCentral
65.
Yang CP, Liang CS, Chang CM, Yang CC, Shih PH, Yau YC, Tang KT, Wang SJ. Comparison of new pharmacologic agents with triptans for treatment of migraine: a systematic review and meta-analysis. JAMA network open. 2021;4(10):e2128544-.
66.
Johnston K, Popoff E, Deighton A, Dabirvaziri P, Harris L, Thiry A, Croop R, Coric V, L’Italien G, Moren J. Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis. Expert Rev of Pharmacoecon Outcomes Res. 2022;22(1):155–66.CrossRef
Metadaten
Titel
The Role of Step Therapy in the Treatment of Migraine
verfasst von
Leon S. Moskatel
Niushen Zhang
Publikationsdatum
05.08.2023
Verlag
Springer US
Erschienen in
Current Pain and Headache Reports / Ausgabe 10/2023
Print ISSN: 1531-3433
Elektronische ISSN: 1534-3081
DOI
https://doi.org/10.1007/s11916-023-01155-w

Weitere Artikel der Ausgabe 10/2023

Current Pain and Headache Reports 10/2023 Zur Ausgabe

Episodic Migraine (S Parikh, Section Editor)

Unique Considerations in Episodic Migraine: Underserved Populations

ACUTE PAIN MEDICINE (R URMAN, SECTION EDITOR)

Low-Level Laser Therapy for Acute Pain: A Comprehensive Review

Episodic Migraine (S Parikh, Section Editor)

Non-CGRP Antagonist/Non-Triptan Options for Migraine Disease Treatment: Clinical Considerations

Chronic Daily Headache (S-J Wang and S-P Chen, Section Editors)

New Daily Persistent Headache (NDPH): Unraveling the Complexities of Diagnosis, Pathophysiology, and Treatment

Chronic Daily Headache (S-J Wang and S-P Chen, Section Editors)

Serological Biomarkers of Chronic Migraine

Hot Topics in Pain and Headache (N Rosen, Section Editor)

Ketamine for Chronic Pain and Mental Health: Regulations, Legalities, and the Growth of Infusion Clinics

Neu im Fachgebiet AINS

Mit dem Seitenschneider gegen das Reißverschluss-Malheur

03.06.2024 Urologische Notfallmedizin Nachrichten

Wer ihn je erlebt hat, wird ihn nicht vergessen: den Schmerz, den die beim Öffnen oder Schließen des Reißverschlusses am Hosenschlitz eingeklemmte Haut am Penis oder Skrotum verursacht. Eine neue Methode für rasche Abhilfe hat ein US-Team getestet.

Schlaganfall: frühzeitige Blutdrucksenkung im Krankenwagen ohne Nutzen

31.05.2024 Apoplex Nachrichten

Der optimale Ansatz für die Blutdruckkontrolle bei Patientinnen und Patienten mit akutem Schlaganfall ist noch nicht gefunden. Ob sich eine frühzeitige Therapie der Hypertonie noch während des Transports in die Klinik lohnt, hat jetzt eine Studie aus China untersucht.

Reanimation bei Kindern – besser vor Ort oder während Transport?

29.05.2024 Reanimation im Kindesalter Nachrichten

Zwar scheint es laut einer Studie aus den USA und Kanada bei der Reanimation von Kindern außerhalb einer Klinik keinen Unterschied für das Überleben zu machen, ob die Wiederbelebungsmaßnahmen während des Transports in die Klinik stattfinden oder vor Ort ausgeführt werden. Jedoch gibt es dabei einige Einschränkungen und eine wichtige Ausnahme.

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren
Bildnachweise